Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.
about
Clinical use of Bevacizumab in treating refractory glaucomaClinical correlates of common corneal neovascular diseases: a literature reviewAttenuation of corneal neovascularization by topical low-molecular-weight heparin-taurocholate 7 without bleeding complicationStability of limbal stem cell deficiency after mechanical and thermal injuries in mice.Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancerEffects of topical and subconjunctival bevacizumab in high-risk corneal transplant survivalAn alkali-burn injury model of corneal neovascularization in the mouse.Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization.Corneal neovascularization: an anti-VEGF therapy review.Accelerating repaired basement membrane after bevacizumab treatment on alkali-burned mouse cornea.Fasudil hydrochloride, a potent ROCK inhibitor, inhibits corneal neovascularization after alkali burns in miceDesiccating Stress-Induced MMP Production and Activity Worsens Wound Healing in Alkali-Burned CorneasObservation on ultrastructure and histopathology of cornea following femtosecond laser-assisted deep lamellar keratoplasty for acute corneal alkaline burns.Inhibition of corneal neovascularization with the combination of bevacizumab and plasmid pigment epithelium-derived factor-synthetic amphiphile INTeraction-18 (p-PEDF-SAINT-18) vector in a rat corneal experimental angiogenesis model.Differential Effects of Dexamethasone and Doxycycline on Inflammation and MMP Production in Murine Alkali-Burned Corneas Associated with Dry Eye.Dexamethasone Drug Eluting Nanowafers Control Inflammation in Alkali-Burned Corneas Associated With Dry Eye.The effect of bevacizumab versus ranibizumab in the treatment of corneal neovascularization: a preliminary study.Corneal Penetrating Elastin-Like Polypeptide Carriers.Corneal transparency: genesis, maintenance and dysfunctionPharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.Galectin-3 Inhibition by a Small-Molecule Inhibitor Reduces Both Pathological Corneal Neovascularization and Fibrosis.Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma.Novel aspects of corneal angiogenic and lymphangiogenic privilege.Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab.Inhibition of NLRP3 Inflammasome Pathway by Butyrate Improves Corneal Wound Healing in Corneal Alkali Burn.Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases.The effect of subconjunctival bevacizumab on corneal neovascularization, inflammation and re-epithelization in a rabbit model.Current and Upcoming Therapies for Ocular Surface Chemical Injuries.Minimally invasive microneedles for ocular drug delivery.Growth inhibition of formed corneal neovascularization following Fosaprepitant treatment.Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapyCorneal penetration of topical and subconjunctival bevacizumab.Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cellsComparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model.The effect of different doses of subconjunctival bevacizumab injection on corneal neovascularization.MMP-8 Is Critical for Dexamethasone Therapy in Alkali-Burned Corneas Under Dry Eye Conditions.Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model.Efficacy of topical bevacizumab in high-risk corneal transplant survival.Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium.
P2860
Q28083405-5D98FBC9-4848-49D9-853F-54C3F8B7B328Q28257676-F072FFFC-2087-424C-91BE-E7DFF039DDF2Q28829757-B633CC85-13BB-429E-BD51-ABDDF4E12D6DQ30797361-2C53F789-76FA-4CB5-A4B3-17E1806A1E40Q33813626-F8BAF93C-5E1E-4FA5-ACB4-6A3615A0957DQ33845555-01DF03D1-D5B0-4B32-B987-A2689F7860A9Q34181129-4F733351-1696-4D0A-A002-FB43C2580241Q34511156-E45A42D1-38B2-4F2A-A439-2C28083CDBE1Q34641522-657A7C1D-0C63-4A99-8B4A-523817074BE5Q34686306-7CD62086-F232-4571-A327-835B5A557610Q35725564-9339F7D7-9C85-4CAF-94A1-81D307092831Q35918360-992A05E1-952A-41B0-B577-7C2AF92B50A0Q36013008-C02E1C2D-83EA-4F5B-8C44-7FC9462635D4Q36820584-811EEBDD-C27C-4600-A354-EF6DF38B586DQ36829083-1866522C-637A-4A81-9E23-8544F0555150Q37055739-FD18264E-3BFD-425F-959A-58ED9EA18C12Q37061085-7D64F9F8-CA87-4C86-8DF3-AE402BDF5284Q37081322-2672B4F0-F017-4134-AC55-A29C300999C1Q37500924-761F00E3-4232-4BA9-8162-F14BD4CB1528Q37549985-44470844-6C89-41E5-AA49-547D81E1F6DAQ37579627-893757E5-487C-4461-B581-8300D393A91FQ37672460-E1DBF248-BF38-4A93-8CEA-D70744949487Q37681157-EBF88E92-ACF4-404B-BADF-A4B3A733D6F5Q37693888-3EA0DD67-BDE8-4F1B-84C7-130C00E8B61DQ37729147-A1652136-4DAD-4334-AD11-9647CC781978Q37815481-8F396E1F-BD68-4BA4-A774-5ED2C0BE7EEFQ38258893-82146989-B1DC-493B-94E8-696C4AC259C0Q38819339-A320C1E0-83C7-4DEB-AAEA-71DA32584F95Q38916649-EB77CBC2-4130-4188-8115-AD730F9135C9Q38958273-B7AAC972-6BC2-4DFB-A375-A90D45730D2EQ39579889-F2BF5015-5D36-4E68-A413-12648BEA7FCCQ39589760-17BC56BF-256B-41D9-A891-D63C0C09AEF5Q39965612-4FF05943-624C-4BF5-8C8F-056A23AE6745Q40018607-E40C73A5-64AA-466D-B5F5-06DC51869AE2Q40060166-D012EACA-5AA6-4113-8D0D-4AE665078A82Q40091988-4EC79F16-481A-4FB6-96F3-588B8AC6F2F6Q40774472-E747C673-380E-486B-B198-ACAD4FD14CA7Q41454864-1C9C80A0-F943-4CDE-81E7-A2EE2D643509Q42933253-B96FE05B-8427-4D7A-8F69-FCFE54AB62C4Q43215465-70D407C5-0635-448E-AEF3-D475D8AEB61F
P2860
Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Safety, penetration and effica ...... arization after chemical burn.
@ast
Safety, penetration and effica ...... arization after chemical burn.
@en
type
label
Safety, penetration and effica ...... arization after chemical burn.
@ast
Safety, penetration and effica ...... arization after chemical burn.
@en
prefLabel
Safety, penetration and effica ...... arization after chemical burn.
@ast
Safety, penetration and effica ...... arization after chemical burn.
@en
P2093
P1433
P1476
Safety, penetration and effica ...... arization after chemical burn.
@en
P2093
Aysegül Tura
Efdal Yoeruek
Focke Ziemssen
Olcay Tatar
Peter Szurman
Salvatore Grisanti
Sigrid Henke-Fahle
Tübingen Bevacizumab Study Group
P304
P356
10.1111/J.1600-0420.2007.01049.X
P577
2007-11-08T00:00:00Z